1.What is the impact of type 2 diabetes mellitus on CYP450 metabolic activities?

Tomlinson, B, Li, YH     More...

Tomlinson, B, Li, YH     Less

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2023, Volume 19, Issue 12, Pages 867-870

收錄情况： WOS SCOPUS

WOS核心合集引用: 0  2022影響因子:  4.3 

2.An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease

Tomlinson, B, Chow,     More...

Tomlinson, B, Chow, E, Chan, P, Lam, CWK     Less

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2021, Volume 17, Issue 12, Pages 1353-1361

收錄情况： WOS SCOPUS

WOS核心合集引用: 5  2022影響因子:  4.3  发表年影響因子:  4.936 

3.Pharmacokinetics of current and emerging treatments for hypercholesterolemia

Tomlinson, B, Chan,     More...

Tomlinson, B, Chan, P, Zhang, YZ, Liu, ZM, Lam, CWK     Less

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2020, Volume 16, Issue 5, Pages 371-385

收錄情况： WOS SCOPUS

WOS核心合集引用: 9  2022影響因子:  4.3  发表年影響因子:  4.481 

4.Metformin transporter pharmacogenomics: insights into drug disposition-where are we now?

Chan, P, Shao, L, To     More...

Chan, P, Shao, L, Tomlinson, B, Zhang, YZ, Liu, ZM     Less

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2018, Volume 14, Issue 11, Pages 1149-1159

收錄情况： WOS SCOPUS

WOS核心合集引用: 15  2022影響因子:  4.3  发表年影響因子:  3.487 

5.Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes

Tomlinson, B, Hu, M,     More...

Tomlinson, B, Hu, M, Zhang, YZ, Chan, P, Liu, ZM     Less

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2017, Volume 13, Issue 2, Pages 211-223

收錄情况： WOS SCOPUS

WOS核心合集引用: 16  2022影響因子:  4.3  发表年影響因子:  3.151 

6.Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes

Tomlinson, B, Hu, M,     More...

Tomlinson, B, Hu, M, Zhang, YZ, Chan, P, Liu, ZM     Less

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2016, Volume 12, Issue 11, Pages 1267-1271

收錄情况： WOS SCOPUS

WOS核心合集引用: 9  2022影響因子:  4.3  发表年影響因子:  3.027 

7.Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin

Hu, M, Tomlinson, B     More...

Hu, M, Tomlinson, B     Less

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2014, Volume 10, Issue 1, Pages 51-65

收錄情况： WOS SCOPUS

WOS核心合集引用: 32  2022影響因子:  4.3  发表年影響因子:  2.831 

8.The pharmacogenetics of beta-adrenergic receptor antagonists in the treatment of hypertension and heart failure

Chan, SW, Hu, M, Tom     More...

Chan, SW, Hu, M, Tomlinson, B     Less

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2012, Volume 8, Issue 7, Pages 767-790

收錄情况： WOS SCOPUS

WOS核心合集引用: 14  2022影響因子:  4.3  发表年影響因子:  2.944 

9.The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins

Hu, MA, To, KKW, Mak     More...

Hu, MA, To, KKW, Mak, VWL, Tomlinson, B     Less

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2011, Volume 7, Issue 1, Pages 49-62

收錄情况： WOS SCOPUS

WOS核心合集引用: 39  2022影響因子:  4.3  发表年影響因子:  3.119 

10.Pharmacokinetic evaluation of lanreotide

Hu, MA, Tomlinson, B     More...

Hu, MA, Tomlinson, B     Less

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2010, Volume 6, Issue 10, Pages 1301-1312

收錄情况： WOS SCOPUS

WOS核心合集引用: 11  2022影響因子:  4.3  发表年影響因子:  3.374